{"preliminary_commentary":{"by_channel":{"x_thread":8,"youtube":2,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03016871\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["nivolumab"],["nivolumab","ICE"]],"indication":"relapsed or refractory Hodgkin lymphoma","name":"NICE","nct_id":"NCT03016871","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nice-nct03016871. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 14 days for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with CR or PR receive nivolumab for an additional 6 weeks. Patients with only SD after 6-week nivolumab treatment receive nivolumab for an additional 6 weeks or receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2 every 21 days for 6 weeks per physician/investigator's discretion. Patients with PD after 6-week nivolumab treatment or patients with PR, SD, or PD after 12-week nivolumab treatment receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.","label":"Cohort A (nivolumab, etoposide, ifosfamide, carboplatin)","type":"EXPERIMENTAL"},{"description":"Patients receive nivolumab IV over 30 minutes on cycle 1 (cycle 1 is 14 days), day 1 in the absence of disease progression or unacceptable toxicity. Beginning in cycle 2, patients receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.","label":"Cohort B (nivolumab, etoposide, ifosfamide, carboplatin)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2027-04-06","type":"ESTIMATED"},"conditions":["Recurrent Hodgkin Lymphoma","Refractory Hodgkin Lymphoma"],"enrollment":{"count":78,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Carboplatin","otherNames":["Blastocarb","Carboplat","Carboplatin Hexal","Carboplatino","Carboplatinum","Carbosin","Carbosol","Carbotec","CBDCA","Displata","Ercar","JM-8","Nealorin","Novoplatinum","Paraplatin","Paraplatin AQ","Paraplatine","Platinwas","Ribocarbo"],"type":"DRUG"},{"name":"Etoposide","otherNames":["Demethyl Epipodophyllotoxin Ethylidine Glucoside","EPEG","Lastet","Toposar","Vepesid","VP 16","VP 16-213","VP-16","VP-16-213","VP16"],"type":"DRUG"},{"name":"Ifosfamide","otherNames":["Asta Z 4942","Asta Z-4942","Cyfos","Holoxan","Holoxane","Ifex","IFO","IFO-Cell","Ifolem","Ifomida","Ifomide","Ifosfamidum","Ifoxan","IFX","Iphosphamid","Iphosphamide","Iso-Endoxan","Isoendoxan","Isophosphamide","Mitoxana","MJF 9325","MJF-9325","Naxamide","Seromida","Tronoxal","Z 4942","Z-4942"],"type":"DRUG"},{"name":"Laboratory Biomarker Analysis","otherNames":[],"type":"OTHER"},{"name":"Nivolumab","otherNames":["BMS-936558","MDX-1106","NIVO","ONO-4538","Opdivo"],"type":"BIOLOGICAL"}],"last_update":"2026-08-25","lead_sponsor":"City of Hope Medical Center","official_title":"A Phase II Trial of Response-Adapted Second-Line Therapy for Hodgkin Lymphoma Using Anti-PD-1 Antibody Nivolumab ? ICE Chemotherapy as a Bridge to Autologous Hematopoietic Cell Transplant (NICE Trial)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2024-01-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Complete Response Rate by Lugano Classification","timeFrame":"From the initial treatment to the end of the treatment, up to 6 months."},{"measure":"Number of Participants With Unacceptable Adverse Events","timeFrame":"From initial treatment to the end of the study, up to 77 months."}],"references":[{"citation":"Mei MG, Lee HJ, Palmer JM, Chen R, Tsai NC, Chen L, McBride K, Smith DL, Melgar I, Song JY, Bonjoc KJ, Armenian S, Nwangwu M, Lee PP, Zain J, Nikolaenko L, Popplewell L, Nademanee A, Chaudhry A, Rosen S, Kwak L, Forman SJ, Herrera AF. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood. 2022 Jun 23;139(25):3605-3616. doi: 10.1182/blood.2022015423.","pmid":"35316328","type":"DERIVED"}],"start_date":{"date":"2017-04-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL","url":"https://clinicaltrials.gov/study/NCT03016871"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nice-nct03016871"}